Literature DB >> 21055684

Nonalcoholic fatty liver disease.

Kathryn Law1, Elizabeth M Brunt.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) significantly contributes to the morbidity and mortality of large proportions of the population across all age ranges, which will continue for the foreseeable future. Since NAFLD and nonalcoholic steatohepatitis were originally described, understanding of pathogenesis, relationships to insulin resistance and the metabolic syndrome, and histopathologic lesions has progressed. However, no clinical or imaging parameters can yet accurately predict inflammatory activity or fibrosis stage across the spectrum of disease. Liver needle biopsy interpretation remains essential in this role; liver biopsy evaluation is also needed for recognition of concurrent (or alternate) liver disease processes. Thus, an understanding of the histologic spectrum of findings in NAFLD and the methods of semiquantitative evaluations used are required for pathologists who sign out liver biopsies. This article describes histologic findings, and provides insights into the pathologic processes and clinical implications across the spectrum of NAFLD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21055684     DOI: 10.1016/j.cld.2010.07.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  21 in total

Review 1.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

Review 2.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

3.  The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio).

Authors:  Thais Ortiz Hammes; Gabriela Lima Pedroso; Carolina Rigatti Hartmann; Thayssa Dalla Costa Escobar; Laisa Beduschi Fracasso; Darlan Pase da Rosa; Norma Possa Marroni; Marilene Porawski; Themis Reverbel da Silveira
Journal:  Dig Dis Sci       Date:  2011-10-14       Impact factor: 3.199

4.  Non-alcoholic fatty liver disease resolution following sleeve gastrectomy.

Authors:  Ardeshir Algooneh; Sulaiman Almazeedi; Salman Al-Sabah; Maha Ahmed; Feras Othman
Journal:  Surg Endosc       Date:  2015-07-21       Impact factor: 4.584

5.  A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model.

Authors:  Srinivas Pittala; Yakov Krelin; Yael Kuperman; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

Review 6.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 7.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

8.  Liver fibrogenesis in non-alcoholic steatohepatitis.

Authors:  Zhaolian Bian; Xiong Ma
Journal:  Front Physiol       Date:  2012-07-11       Impact factor: 4.566

Review 9.  Treatment of nonalcoholic steatohepatitis in adults: present and future.

Authors:  S Gitto; G Vitale; E Villa; P Andreone
Journal:  Gastroenterol Res Pract       Date:  2015-03-18       Impact factor: 2.260

10.  Probiotic as a novel treatment strategy against liver disease.

Authors:  Abbas Ali Imani Fooladi; Hamideh Mahmoodzadeh Hosseini; Mohammad Reza Nourani; Soghra Khani; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-02-25       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.